|Articles|June 5, 2013

Trends in Patient Chemo Care Add Strain to Medicare

A federal policy shift has triggered a decline in patients receiving less-costly chemotherapy in physicians’ offices and a surge of those in more expensive hospital outpatient departments, according to a study released Monday. The trend, experts say, could have lasting effects on the quality of patient care, the existence of independent clinics and the future of Medicare.

Moran Co., a Washington-based healthcare research firm, confirmed that Medicare payments for fee-for-service hospital-based chemotherapy treatments have increased significantly while those for physicians’ offices have fallen.

According to the study, between 2005 and 2011 Medicare payments for chemotherapy administration in hospitals tripled to $300.9 million from $98.3 million, while payments for physician clinic chemotherapy administration dropped by 14.5 percent to $433.8 million from $507.5 million.

Read the full story here: http://bit.ly/14vD0YE

Source: Medill Reports Chicago

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo